A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
NCT07628049 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 1808
Last updated 2026-07-08
Summary
The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.
Conditions
- Respiratory Syncytial Virus Infections+Metapneumovirus
Interventions
- BIOLOGICAL
-
RSV/hMPV_W low dose vaccine
RSV/hMPV\_W low dose vaccine administered intramuscularly.
- BIOLOGICAL
-
RSV/hMPV_W medium dose vaccine
RSV/hMPV\_W medium dose vaccine administered intramuscularly.
- BIOLOGICAL
-
RSV/hMPV_W high dose vaccine
RSV/hMPV\_W high dose vaccine administered intramuscularly.
- BIOLOGICAL
-
RSV/hMPV_X low dose vaccine
RSV/hMPV\_X low dose vaccine administered intramuscularly.
- BIOLOGICAL
-
RSV/hMPV_X medium dose vaccine
RSV/hMPV\_X medium dose vaccine administered intramuscularly.
- BIOLOGICAL
-
RSV/hMPV_X high dose vaccine
RSV/hMPV\_X high dose vaccine administered intramuscularly.
- BIOLOGICAL
-
hMPV_Y low dose vaccine
hMPV\_Y low dose vaccine administered intramuscularly.
- BIOLOGICAL
-
hMPV_Y medium dose vaccine
hMPV\_Y medium dose vaccine administered intramuscularly.
- BIOLOGICAL
-
hMPV_Y high dose vaccine
hMPV\_Y high dose vaccine administered intramuscularly.
- BIOLOGICAL
-
hMPV_Z low dose vaccine
hMPV\_Z low dose vaccine administered intramuscularly.
- BIOLOGICAL
-
hMPV_Z medium dose vaccine
hMPV\_Z medium dose vaccine administered intramuscularly.
- BIOLOGICAL
-
hMPV_Z high dose vaccine
hMPV\_Z high dose vaccine administered intramuscularly.
- BIOLOGICAL
-
Control vaccine
Control vaccine administered intramuscularly.
- COMBINATION_PRODUCT
-
Placebo
Placebo administered intramuscularly.
- BIOLOGICAL
-
RSV/hMPV_V low dose vaccine
RSV/hMPV\_V low dose vaccine administered intramuscularly.
- BIOLOGICAL
-
RSV/hMPV_V medium dose vaccine
RSV/hMPV\_V medium dose vaccine administered intramuscularly.
- BIOLOGICAL
-
RSV/hMPV_V high dose vaccine
RSV/hMPV\_V high dose vaccine administered intramuscularly.
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- QUADRUPLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-06-05
- Primary Completion
- 2029-04-05
- Completion
- 2029-04-05
- FDA Drug
- Yes
Countries
- United States
- Australia
Study Locations
More Related Trials
-
A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults
NCT02491463 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults
NCT03814590 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
NCT06583031 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
NCT02298179 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older
NCT03502707 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults
NCT07295028 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older
NCT05639894 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older
NCT05327816 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
NCT03572062 ·Status: TERMINATED ·Phase: PHASE2
-
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
NCT06686654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
NCT04144348 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
NCT06216093 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older
NCT07128121 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants
NCT02927873 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults
NCT04798001 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
NCT06067230 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older
NCT06604767 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults
NCT06556147 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV
NCT03636906 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above
NCT05590403 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older
NCT04908683 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older
NCT07208461 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age
NCT05903183 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of the Safety and Immunogenicity of a Live Attenuated Human Metapneumovirus Vaccine
NCT01255410 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines
NCT01905215 ·Status: COMPLETED ·Phase: PHASE1